Literature DB >> 15550942

Tularaemia: bioterrorism defence renews interest in Francisella tularensis.

Petra C F Oyston1, Anders Sjostedt, Richard W Titball.   

Abstract

Francisella tularensis is a highly infectious aerosolizable intracellular pathogen that is capable of causing a debilitating or fatal disease with doses as low as 25 colony-forming units. There is no licensed vaccine available. Since the 1950s there has been concern that F. tularensis could be used as a biological threat agent, and it has received renewed attention recently owing to concerns about bioterrorism. The International Conference on Tularaemia in 2003 attracted more than 200 delegates, twice the number of participants as previous meetings. This is a reflection of the increased funding of research on this pathogen, particularly in the United States.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550942     DOI: 10.1038/nrmicro1045

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  276 in total

1.  Deletion of ripA alleviates suppression of the inflammasome and MAPK by Francisella tularensis.

Authors:  Max Tze-Han Huang; Brittany L Mortensen; Debra J Taxman; Robin R Craven; Sharon Taft-Benz; Todd M Kijek; James R Fuller; Beckley K Davis; Irving Coy Allen; Willie June Brickey; Denis Gris; Haitao Wen; Thomas H Kawula; Jenny Pan-Yun Ting
Journal:  J Immunol       Date:  2010-10-04       Impact factor: 5.422

2.  Francisella tularensis reveals a disparity between human and mouse NLRP3 inflammasome activation.

Authors:  Maninjay K Atianand; Ellen B Duffy; Aaloki Shah; Supriya Kar; Meenakshi Malik; Jonathan A Harton
Journal:  J Biol Chem       Date:  2011-09-19       Impact factor: 5.157

3.  Francisella tularensis Schu S4 O-antigen and capsule biosynthesis gene mutants induce early cell death in human macrophages.

Authors:  Stephen R Lindemann; Kaitian Peng; Matthew E Long; Jason R Hunt; Michael A Apicella; Denise M Monack; Lee-Ann H Allen; Bradley D Jones
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

4.  Generation and characterization of hybridoma antibodies for immunotherapy of tularemia.

Authors:  Zhaohua Lu; Marly I Roche; Julia H Hui; Berkay Unal; Philip L Felgner; Sunita Gulati; Guillermo Madico; Jacqueline Sharon
Journal:  Immunol Lett       Date:  2007-08-08       Impact factor: 3.685

5.  Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy.

Authors:  Anne G Savitt; Patricio Mena-Taboada; Gloria Monsalve; Jorge L Benach
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

6.  Human Cases of Tularemia in Armenia, 1996-2012.

Authors:  Syuzanna Melikjanyan; Karo Palayan; Artavazd Vanyan; Lilit Avetisyan; Nune Bakunts; Marine Kotanyan; Marta Guerra
Journal:  Am J Trop Med Hyg       Date:  2017-07-19       Impact factor: 2.345

7.  Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS.

Authors:  Michael D Valentino; Lucinda L Hensley; Denise Skrombolas; Pamela L McPherson; Matthew D Woolard; Thomas H Kawula; Jeffrey A Frelinger; John G Frelinger
Journal:  Mol Immunol       Date:  2009-02-23       Impact factor: 4.407

8.  Francisella tularensis phagosomal escape does not require acidification of the phagosome.

Authors:  Daniel L Clemens; Bai-Yu Lee; Marcus A Horwitz
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

9.  FipB, an essential virulence factor of Francisella tularensis subsp. tularensis, has dual roles in disulfide bond formation.

Authors:  Aiping Qin; Yan Zhang; Melinda E Clark; Meaghan M Rabideau; Luis R Millan Barea; Barbara J Mann
Journal:  J Bacteriol       Date:  2014-08-04       Impact factor: 3.490

10.  Genome-wide screen in Francisella novicida for genes required for pulmonary and systemic infection in mice.

Authors:  Petra S Kraemer; Allison Mitchell; Mark R Pelletier; Larry A Gallagher; Mike Wasnick; Laurence Rohmer; Mitchell J Brittnacher; Colin Manoil; Shawn J Skerett; Nina R Salama
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.